Comparing Coeptis Therapeutics (NASDAQ:COEP) & ProKidney (NASDAQ:PROK)

ProKidney (NASDAQ:PROK) and Coeptis Therapeutics (NASDAQ:COEP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.

Analyst Recommendations

This is a summary of current recommendations and price targets for ProKidney and Coeptis Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProKidney	0	1	5	0	2.83
Coeptis Therapeutics	0	0	2	0	3.00

ProKidney presently has a consensus price target of $15.33, indicating a potential upside of 83.63%. Coeptis Therapeutics has a consensus price target of $5.00, indicating a potential upside of 407.61%. Given Coeptis Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Coeptis Therapeutics is more favorable than ProKidney.

Valuation & Earnings

This table compares ProKidney and Coeptis Therapeutics’ revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProKidney	N/A	N/A	-$108.03 million	($0.54)	-15.46
Coeptis Therapeutics	$80,000.00	309.55	-$37.57 million	N/A	N/A

Coeptis Therapeutics has higher revenue and earnings than ProKidney.

Institutional & Insider Ownership

16.9% of ProKidney shares are held by institutional investors. Comparatively, 13.3% of Coeptis Therapeutics shares are held by institutional investors. 45.0% of ProKidney shares are held by insiders. Comparatively, 36.6% of Coeptis Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares ProKidney and Coeptis Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProKidney	N/A	N/A	-7.33%
Coeptis Therapeutics	N/A	-1,949.40%	-144.14%

Summary

ProKidney beats Coeptis Therapeutics on 5 of the 9 factors compared between the two stocks.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture that is in Phase I for REACT in patients with Congenital Anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. is headquartered in Wexford, Pennsylvania.